Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings Inc (RVPH) focuses on developing novel therapies for central nervous system disorders and cardiometabolic diseases through its proprietary drug discovery platform. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access comprehensive coverage of Reviva's progress including clinical trial results, regulatory submissions, and strategic partnerships. Our curated news collection enables efficient tracking of the company's lead candidates like Brilaroxazine (RP5063) and RP1208 through critical development phases.
Key updates include progress in neuropsychiatric drug development, intellectual property advancements, and financial reporting. The resource serves investors requiring detailed insights into therapeutic pipeline maturation and market positioning within competitive CNS/pharma sectors.
Bookmark this page for streamlined access to Reviva's latest developments. Check regularly for authoritative reporting on clinical data releases, FDA communications, and research collaborations that shape the company's trajectory in biopharmaceutical innovation.
Reviva Pharmaceuticals announced an update on the ongoing 1-year open-label extension (OLE) study of Brilaroxazine in patients with schizophrenia. The study aims to assess the long-term safety and tolerability of the drug. As of November 12, 2024, 108 patients have completed 12 months of treatment, and over 250 patients have completed 6 months. Long-term safety data from 100 patients who completed one year of treatment is vital for the planned New Drug Application (NDA) to the FDA. Topline data from this study is expected in December 2024, with the full 12-month safety study concluding in Q1 2025.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced it will present positive speech latency data for brilaroxazine in schizophrenia from their Phase 3 RECOVER trial at the CNS Summit 2024. The presentation titled 'Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine' will be delivered as a poster presentation by Dr. Jan Sedway from WCG Clinical on November 12th in Boston, Massachusetts.
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on central nervous system, inflammatory and cardiometabolic diseases, has announced its participation in the UBS Global Healthcare Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat at the conference, which is scheduled for November 11-14, 2024, in Rancho Palos Verdes, CA. The presentation is specifically scheduled for Thursday, November 14, 2024, at 8:00 a.m. PT.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focusing on central nervous system (CNS), inflammatory, and cardiometabolic diseases, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat during the event.
The virtual summit is scheduled for October 15-17, 2024, with Reviva's fireside chat taking place on Tuesday, October 15, 2024, at 3:30 p.m. ET. Interested parties can access the event through a provided registration link. This participation underscores Reviva's commitment to engaging with the healthcare investment community and showcasing its progress in developing therapies for unmet medical needs.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications'.
Reviva focuses on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases. The conference will provide an opportunity for one-on-one investor meetings with Reviva's management team. Interested parties are advised to contact their ROTH representative for registration and meeting scheduling.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company, announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will deliver a webcasted presentation at 3:30 p.m. ET and host one-on-one meetings with investors.
The virtual event will be accessible through various platforms, including the conference registration page, Lytham Partners' conference home page, and Reviva's website. Investors can arrange meetings with management by contacting Lytham Partners or registering for the event online.
Reviva focuses on developing therapies for central nervous system (CNS), inflammatory, and cardiometabolic diseases, addressing unmet medical needs in these areas.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) has announced new vocal biomarker data from its Phase 3 RECOVER trial of brilaroxazine in schizophrenia. The data, presented during a virtual key opinion leader event, showed statistically significant speech latency results, reinforcing the drug's strong efficacy for negative symptoms and other key symptom domains of schizophrenia.
Highlights include:
- Brilaroxazine demonstrated a safety profile comparable to placebo
- Strong efficacy across major symptom domains, including negative symptoms
- Vocal biomarker data provides an objective tool supporting primary and secondary endpoints
- Additional data from an ongoing open-label extension study expected in Q4 2024
Experts emphasized brilaroxazine's potential to address unmet needs in schizophrenia treatment, particularly its efficacy for negative symptoms and cognition, coupled with a strong efficacy-to-side-effect ratio.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focusing on CNS, inflammatory, and cardiometabolic diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024.
Key details include:
- CEO Dr. Laxminarayan Bhat will deliver a corporate update
- A pre-recorded presentation will be available on-demand from September 9, 7:00 a.m. ET
- Management will participate in virtual one-on-one meetings
Investors can access the presentation via a provided webcast link and arrange meetings with management through H.C. Wainwright sales representatives.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) has announced a virtual key opinion leader (KOL) event scheduled for September 4, 2024, at 2:00 PM ET. The event will focus on discussing vocal biomarker data from the Phase 3 RECOVER trial of brilaroxazine in schizophrenia. Two experts, Dr. Brian Kirkpatrick and Dr. Mark Opler, will lead the discussion on:
1. The unmet medical need and current treatment landscape for schizophrenia patients
2. Application of speech latency as an objective vocal biomarker in schizophrenia trials
3. Results of the vocal biomarker data and their relationship to primary and secondary endpoints
The event aims to provide insights into the efficacy of brilaroxazine in treating schizophrenia symptoms, particularly focusing on negative symptoms, social functioning, and cognition.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) has announced the pricing of an underwritten offering of 4,761,905 shares of common stock (or pre-funded warrants) and investor warrants to purchase up to 4,761,905 shares. The combined offering price is $1.05 per share, priced at-the-market under Nasdaq rules. The company expects to receive gross proceeds of approximately $5.0 million.
The offering includes warrants with an exercise price of $0.7964 per share, exercisable immediately and expiring in five years. Reviva intends to use the proceeds to fund research and development activities, including its Phase 3 RECOVER-2 trial, and for working capital. The offering is expected to close on or about August 22, 2024.
Additionally, Reviva has agreed to amend certain existing warrants held by the investor, reducing their exercise price to $0.7964 per share.
